Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
VRL Logistics board to meet on July 4 to consider bonus share issue
VRL Logistics’ board will meet on July 4, 2025, to consider issuing bonus shares to eligible shareholders, with the record date to be announced later.